The present stock price for Lineage Cell Therapeutics Inc (LCTX) is $1.18. In the last trading session, the stock made a considerable jump, reaching $9.0 after an opening price of $1.18. The stock briefly fell to $2.0 before ending the session at $1.02.
Lineage Cell Therapeutics Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $1.21 on 07/28/25, while the lowest price for the same duration was marked at $0.37 on 04/09/25.
52-week price history of LCTX Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Lineage Cell Therapeutics Inc’s current trading price is -2.40% away from its 52-week high, while its distance from the 52-week low is 223.47%. The stock’s price range during this period has spanned from $0.37 to $1.21. In the Healthcare sector, the Lineage Cell Therapeutics Inc’s shares surpassed a trading volume of approximately 1.9 million for the day, which was noticeably lower compared to the average daily volume of 9.2.38 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly rise of 151.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 269.68M and boasts a workforce of 77 employees.
A Closer Look at Analysts’ Ratings for Lineage Cell Therapeutics Inc
As of right now, 4 analysts are rating Lineage Cell Therapeutics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7287, with a change in price of +0.6337. Similarly, Lineage Cell Therapeutics Inc recorded 1,915,183 in trading volume during the last 100 days, posting a change of +118.16%.
Examining LCTX’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
Today, Lineage Cell Therapeutics Inc’s raw stochastic average for the past 50 days stands at 92.86%, indicating a rise from the raw stochastic average of the last 20 days, which was 85.73%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 51.26% and 38.18% respectively.
LCTX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price gain of 42.39% this year. Over the last six months, there has been a weaker performance of 72.41%. The price of LCTX fallen by 19.29% during the last 30 days period. For the last 5-days stocks have improved 19.97%.
